Rheumatoid arthritis
Conditions
Interventions
Injection of etanercept by 50 mg/week for one year
Injection of etanercept by 25 mg/week for one year
Sponsors
Team RA, Rheumatosurgery, Osaka City University Medical School
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All patients must have active rheumatoid arthritis at enrollment with requirements that they have more than 4 swollen joints or more than 4 tender joints (using a 68-joint count). The elevations in the level of C reactive protein or erthrocyte sedimentation rate are not required. DAS(disease activity score)28 must be over 3.2 or patients must desire the use of biologics when DAS28<3.2.
Exclusion criteria
Exclusion criteria: Cases who have Joint destruction on hand and foot, in whom we can't measure modified Sharp score. Except Eetanercept dose, there is no restriction for other medicine use.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total Sharp score (erosion and joint space narrowing) | — |
Countries
Japan
Contacts
Public ContactTatsuya Koike
Osaka City University Medical School Rheumatosurgery
Outcome results
None listed